Next Article in Journal
Polyamine Catabolism in Acute Kidney Injury
Next Article in Special Issue
Pharmacological Targeting of GLUT1 to Control Autoreactive T Cell Responses
Previous Article in Journal
Complete Sequence, Multichromosomal Architecture and Transcriptome Analysis of the Solanum tuberosum Mitochondrial Genome
Previous Article in Special Issue
BET Proteins Are Required for Transcriptional Activation of the Senescent Islet Cell Secretome in Type 1 Diabetes
Open AccessReview

New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes

1
Biochemistry Area, Health Science Department, Faculty of Health Sciences, Public University of Navarra, 31008 Pamplona, Spain
2
Diabetes Research Group at Sanford Research, Sioux Falls, SD 57104, USA
3
Incyte Corporation, Wilmington, DE 19803, USA
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(19), 4789; https://doi.org/10.3390/ijms20194789
Received: 29 August 2019 / Revised: 18 September 2019 / Accepted: 20 September 2019 / Published: 26 September 2019
(This article belongs to the Special Issue Advances in Immunotherapeutic Approaches to Type 1 Diabetes)
Type 1 diabetes mellitus (T1D) is an autoimmune illness that affects millions of patients worldwide. The main characteristic of this disease is the destruction of pancreatic insulin-producing beta cells that occurs due to the aberrant activation of different immune effector cells. Currently, T1D is treated by lifelong administration of novel versions of insulin that have been developed recently; however, new approaches that could address the underlying mechanisms responsible for beta cell destruction have been extensively investigated. The strategies based on immunotherapies have recently been incorporated into a panel of existing treatments for T1D, in order to block T-cell responses against beta cell antigens that are very common during the onset and development of T1D. However, a complete preservation of beta cell mass as well as insulin independency is still elusive. As a result, there is no existing T1D targeted immunotherapy able to replace standard insulin administration. Presently, a number of novel therapy strategies are pursuing the goals of beta cell protection and normoglycemia. In the present review we explore the current state of immunotherapy in T1D by highlighting the most important studies in this field, and envision novel strategies that could be used to treat T1D in the future. View Full-Text
Keywords: diabetes; autoimmunity; insulin; immunotherapy and clinical trials diabetes; autoimmunity; insulin; immunotherapy and clinical trials
Show Figures

Figure 1

MDPI and ACS Style

Cabello-Olmo, M.; Araña, M.; Radichev, I.; Smith, P.; Huarte, E.; Barajas, M. New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes. Int. J. Mol. Sci. 2019, 20, 4789.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop